Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database. (Q54420490)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24352344

Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database. (English)

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24352344

0 references

object named as

Virginie Bres

4

0 references

Jean-Louis Montastruc

8

object named as

Jean-Louis Montastruc

1 reference

Europe PubMed Central

29 May 2018

author name string

Jean-Luc Faillie

1

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24352344

Samy Babai

2

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24352344

Sabrina Crépin

3

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24352344

Marie-Laure Laroche

5

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24352344

Hervé Le Louet

6

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24352344

Pierre Petit

7

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24352344

Dominique Hillaire-Buys

9

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24352344

French Pharmacovigilance Centers Network

10

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24352344

publication date

19 December 2013

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24352344

Acta Diabetologica

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24352344

51

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24352344

3

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24352344

491-497

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24352344

https://scigraph.springernature.com/pub.10.1007/s00592-013-0544-0

0 references

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

Data mining in pharmacovigilance: the need for a balanced perspective

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database.

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

The role of data mining in pharmacovigilance

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

Application of data mining techniques in pharmacovigilance

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

Quantitative signal detection using spontaneous ADR reporting

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case/non-case study in the French pharmacovigilance system database

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

Drug-induced pancreatitis : incidence, management and prevention

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

Under-reporting of adverse drug reactions : a systematic review

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

Reports of pancreatitis are 20-30 times more likely with GLP-1 drugs, analysis finds

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

On the assessment of adverse drug reactions from spontaneous reporting systems: the influence of under-reporting on odds ratios

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

Acute pancreatitis in association with type 2 diabetes and antidiabetic drugs: a population-based cohort study

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

Was the thrombotic risk of rofecoxib predictable from the French Pharmacovigilance Database before 30 September 2004?

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe?

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

Incretin therapy and islet pathology: a time for caution

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

A cohort study of acute pancreatitis in relation to exenatide use.

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

Exenatide therapy and the risk of pancreatitis and pancreatic cancer in a privately insured population

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study.

1 reference

https://api.crossref.org/works/10.1007%2FS00592-013-0544-0

21 January 2018

Identifiers

10.1007/S00592-013-0544-0

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24352344

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24352344

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54420490&oldid=1156810473"